Drug Profile
Recombinant human insulin - Sanofi
Alternative Names: HR 1799; Insulin HPR; Insulin Human Winthrop; Insuman; Insuman Comb 25; Insuman ImplantableLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Hoechst Marion Roussel Deutschland GmbH
- Developer Sanofi
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 02 Jul 2019 Recombinant human insulin is not yet available for type 1 diabetes in European Union (Intraperitoneal)
- 01 Feb 2018 Sanofi completes a phase III trial for Type-1 diabetes mellitus in Belgium, France, Netherlands and Sweden (Intraperitoneal) (NCT01194882)
- 23 Mar 2015 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus in China (SC)